Logo Image
  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CE
  • Resources
  • Subscribe

Brian A. Jonas, MD, PhD, FACP

Articles by Brian A. Jonas, MD, PhD, FACP

a vibrant microscopic view of malignant hematologic cells, their structure distorted and disorganized, while GFH009, represented by a glowing pathway | Image Caption: catalin | stock.adobe.com

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

ByVera Pervitsky, PharmD, BCOP, BCPS,Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA,Mimi Lo, PharmD, BCOP, BCPS,Rebecca Young, PharmD, BCOP,Benjamin Moskoff, PharmD, BCOP,Yunyi Ren, MS,Machelle Wilson, PhD,Brian A. Jonas, MD, PhD, FACP,Marisela Banez, PharmD, BCOP, BCPS,Julie Guglielmo, PharmD, BCOP

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Latest Updated Articles